Concepts (221)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia, Sickle Cell | 16 | 2023 | 331 | 2.680 |
Why?
|
| Hydroxyurea | 9 | 2016 | 82 | 1.650 |
Why?
|
| Antisickling Agents | 5 | 2013 | 18 | 1.010 |
Why?
|
| Iron | 5 | 2009 | 271 | 0.780 |
Why?
|
| Fetal Hemoglobin | 4 | 2016 | 28 | 0.720 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2024 | 2640 | 0.640 |
Why?
|
| Stroke | 3 | 2023 | 990 | 0.560 |
Why?
|
| Phosphoglycerate Kinase | 2 | 2006 | 7 | 0.520 |
Why?
|
| Anemia, Hemolytic | 2 | 2006 | 30 | 0.510 |
Why?
|
| Exome | 3 | 2017 | 1034 | 0.500 |
Why?
|
| Mutation, Missense | 3 | 2020 | 875 | 0.490 |
Why?
|
| Genetic Variation | 5 | 2024 | 1502 | 0.440 |
Why?
|
| DNA Damage | 5 | 2024 | 513 | 0.420 |
Why?
|
| Pyrophosphatases | 1 | 2013 | 21 | 0.410 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2013 | 65 | 0.410 |
Why?
|
| Erythrocytes | 2 | 2021 | 219 | 0.410 |
Why?
|
| Antimicrobial Cationic Peptides | 3 | 2007 | 32 | 0.410 |
Why?
|
| Membrane Proteins | 2 | 2013 | 1527 | 0.400 |
Why?
|
| Iron Overload | 2 | 2009 | 16 | 0.390 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 2 | 2024 | 49 | 0.390 |
Why?
|
| Micronuclei, Chromosome-Defective | 1 | 2010 | 9 | 0.340 |
Why?
|
| Promoter Regions, Genetic | 4 | 2013 | 1328 | 0.330 |
Why?
|
| Inflammasomes | 2 | 2022 | 150 | 0.330 |
Why?
|
| Sequence Analysis, DNA | 2 | 2016 | 1756 | 0.320 |
Why?
|
| Genetic Markers | 1 | 2011 | 604 | 0.320 |
Why?
|
| beta-Thalassemia | 1 | 2009 | 27 | 0.320 |
Why?
|
| Haplotypes | 3 | 2013 | 522 | 0.310 |
Why?
|
| Nuclear Proteins | 4 | 2024 | 1265 | 0.310 |
Why?
|
| Caspase 2 | 2 | 2024 | 28 | 0.310 |
Why?
|
| Intestinal Absorption | 2 | 2007 | 190 | 0.300 |
Why?
|
| Erythrocyte Transfusion | 1 | 2009 | 130 | 0.290 |
Why?
|
| Mutation | 5 | 2024 | 5849 | 0.280 |
Why?
|
| Liver | 3 | 2009 | 1749 | 0.270 |
Why?
|
| Genomics | 1 | 2014 | 1499 | 0.270 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2024 | 3160 | 0.270 |
Why?
|
| Hemochromatosis | 1 | 2007 | 33 | 0.260 |
Why?
|
| Amidohydrolases | 1 | 2006 | 23 | 0.260 |
Why?
|
| Pyridoxal Kinase | 1 | 2006 | 2 | 0.260 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2007 | 97 | 0.260 |
Why?
|
| Receptors, Transferrin | 1 | 2006 | 10 | 0.250 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2006 | 64 | 0.250 |
Why?
|
| Gene Expression Regulation | 2 | 2012 | 2522 | 0.240 |
Why?
|
| Child, Preschool | 13 | 2024 | 14030 | 0.240 |
Why?
|
| Child | 16 | 2024 | 24436 | 0.240 |
Why?
|
| Hemolysis | 3 | 2022 | 112 | 0.230 |
Why?
|
| Genome-Wide Association Study | 3 | 2024 | 1689 | 0.230 |
Why?
|
| UDPglucose-Hexose-1-Phosphate Uridylyltransferase | 1 | 2004 | 3 | 0.220 |
Why?
|
| Alcohol Drinking | 1 | 2007 | 346 | 0.220 |
Why?
|
| Gene Transfer Techniques | 1 | 2006 | 357 | 0.220 |
Why?
|
| Antigens, CD | 1 | 2006 | 432 | 0.220 |
Why?
|
| Adolescent | 13 | 2024 | 19373 | 0.210 |
Why?
|
| Wnt Signaling Pathway | 1 | 2024 | 191 | 0.210 |
Why?
|
| Apoptosis | 2 | 2024 | 1806 | 0.190 |
Why?
|
| Nervous System Diseases | 1 | 2006 | 375 | 0.190 |
Why?
|
| Substance-Related Disorders | 1 | 2006 | 461 | 0.190 |
Why?
|
| Humans | 32 | 2024 | 125392 | 0.180 |
Why?
|
| Caspases, Initiator | 1 | 2021 | 6 | 0.180 |
Why?
|
| Cohort Studies | 4 | 2020 | 4824 | 0.180 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2021 | 28 | 0.180 |
Why?
|
| Inflammation | 3 | 2022 | 1446 | 0.180 |
Why?
|
| Rh-Hr Blood-Group System | 1 | 2020 | 11 | 0.180 |
Why?
|
| Carrier Proteins | 3 | 2016 | 1022 | 0.180 |
Why?
|
| Brain Ischemia | 1 | 2023 | 265 | 0.170 |
Why?
|
| Caspases | 1 | 2021 | 162 | 0.170 |
Why?
|
| Blood Group Antigens | 1 | 2020 | 73 | 0.170 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2019 | 12 | 0.160 |
Why?
|
| Cell Proliferation | 2 | 2024 | 2314 | 0.160 |
Why?
|
| Blood Cells | 1 | 2019 | 50 | 0.160 |
Why?
|
| Endothelial Progenitor Cells | 1 | 2019 | 11 | 0.160 |
Why?
|
| Drug Resistance | 1 | 2020 | 257 | 0.160 |
Why?
|
| Thrombocytopenia | 1 | 2021 | 226 | 0.160 |
Why?
|
| Endothelial Cells | 1 | 2022 | 526 | 0.160 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2020 | 139 | 0.150 |
Why?
|
| Hepcidins | 3 | 2007 | 19 | 0.150 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2024 | 537 | 0.150 |
Why?
|
| Chronic Disease | 3 | 2009 | 1201 | 0.150 |
Why?
|
| Autoimmune Diseases | 1 | 2021 | 251 | 0.150 |
Why?
|
| Gene Frequency | 3 | 2020 | 726 | 0.140 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 320 | 0.140 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2012 | 1016 | 0.140 |
Why?
|
| Maximum Tolerated Dose | 2 | 2014 | 163 | 0.140 |
Why?
|
| Macrophages | 1 | 2021 | 626 | 0.140 |
Why?
|
| Genotype | 4 | 2024 | 2568 | 0.130 |
Why?
|
| Metalloendopeptidases | 1 | 2016 | 101 | 0.130 |
Why?
|
| Male | 15 | 2024 | 61663 | 0.130 |
Why?
|
| Albuminuria | 1 | 2016 | 103 | 0.130 |
Why?
|
| Transcriptome | 1 | 2022 | 955 | 0.130 |
Why?
|
| Polymorphism, Genetic | 2 | 2013 | 818 | 0.130 |
Why?
|
| beta-Globins | 2 | 2013 | 6 | 0.120 |
Why?
|
| Glucosephosphate Dehydrogenase | 2 | 2013 | 16 | 0.120 |
Why?
|
| Thrombosis | 1 | 2019 | 526 | 0.110 |
Why?
|
| Female | 14 | 2024 | 66885 | 0.110 |
Why?
|
| Open Reading Frames | 1 | 2014 | 211 | 0.110 |
Why?
|
| Repressor Proteins | 3 | 2016 | 813 | 0.110 |
Why?
|
| Risk Factors | 4 | 2016 | 10331 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 1698 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 2 | 2006 | 1586 | 0.100 |
Why?
|
| Heme | 2 | 2022 | 52 | 0.090 |
Why?
|
| RNA | 2 | 2022 | 570 | 0.090 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 2011 | 9 | 0.090 |
Why?
|
| Interleukin-1beta | 2 | 2022 | 162 | 0.090 |
Why?
|
| Mice | 6 | 2024 | 17637 | 0.090 |
Why?
|
| Pharmacogenetics | 1 | 2011 | 184 | 0.090 |
Why?
|
| Micronucleus Tests | 1 | 2010 | 7 | 0.090 |
Why?
|
| Infant | 5 | 2024 | 12518 | 0.090 |
Why?
|
| Transcription Factors | 3 | 2016 | 2593 | 0.080 |
Why?
|
| Brazil | 2 | 2023 | 122 | 0.080 |
Why?
|
| Time | 1 | 2010 | 92 | 0.080 |
Why?
|
| DNA Mutational Analysis | 2 | 2011 | 794 | 0.080 |
Why?
|
| Signal Transduction | 3 | 2012 | 4536 | 0.080 |
Why?
|
| Phenotype | 2 | 2016 | 4263 | 0.080 |
Why?
|
| DNA-Binding Proteins | 2 | 2014 | 2048 | 0.080 |
Why?
|
| Cytoplasm | 1 | 2009 | 296 | 0.080 |
Why?
|
| Adult | 7 | 2023 | 29692 | 0.070 |
Why?
|
| Chromosome Aberrations | 1 | 2011 | 614 | 0.070 |
Why?
|
| Alleles | 3 | 2020 | 1615 | 0.070 |
Why?
|
| Stress, Physiological | 1 | 2009 | 254 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2016 | 6168 | 0.070 |
Why?
|
| Luminescence | 1 | 2007 | 16 | 0.070 |
Why?
|
| Response Elements | 1 | 2007 | 97 | 0.070 |
Why?
|
| Linear Models | 1 | 2009 | 686 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 2 | 2007 | 4406 | 0.070 |
Why?
|
| Mice, Inbred AKR | 1 | 2007 | 14 | 0.070 |
Why?
|
| Hemochromatosis Protein | 1 | 2007 | 22 | 0.070 |
Why?
|
| Endotoxins | 1 | 2007 | 48 | 0.070 |
Why?
|
| Luciferases | 1 | 2007 | 131 | 0.070 |
Why?
|
| Animals | 6 | 2024 | 34241 | 0.070 |
Why?
|
| Spain | 1 | 2006 | 60 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2006 | 140 | 0.060 |
Why?
|
| Solubility | 1 | 2006 | 139 | 0.060 |
Why?
|
| Linkage Disequilibrium | 1 | 2006 | 309 | 0.060 |
Why?
|
| Migraine Disorders | 1 | 2006 | 63 | 0.060 |
Why?
|
| Retinal Degeneration | 1 | 2006 | 93 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 1711 | 0.060 |
Why?
|
| Protein Folding | 1 | 2006 | 215 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2006 | 359 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2007 | 279 | 0.060 |
Why?
|
| UTP-Hexose-1-Phosphate Uridylyltransferase | 1 | 2004 | 5 | 0.060 |
Why?
|
| Galactosemias | 1 | 2004 | 14 | 0.060 |
Why?
|
| Gene Expression | 1 | 2009 | 1560 | 0.060 |
Why?
|
| Cell Self Renewal | 1 | 2024 | 43 | 0.060 |
Why?
|
| Cells, Cultured | 3 | 2021 | 3056 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 1 | 2006 | 767 | 0.050 |
Why?
|
| Alu Elements | 1 | 2004 | 65 | 0.050 |
Why?
|
| Models, Genetic | 1 | 2006 | 760 | 0.050 |
Why?
|
| ADAMTS Proteins | 1 | 2023 | 9 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2004 | 344 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2009 | 3746 | 0.050 |
Why?
|
| Microfluidics | 1 | 2022 | 21 | 0.050 |
Why?
|
| Base Sequence | 1 | 2006 | 3103 | 0.050 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2022 | 113 | 0.050 |
Why?
|
| Alarmins | 1 | 2021 | 5 | 0.050 |
Why?
|
| Developmental Disabilities | 1 | 2006 | 712 | 0.040 |
Why?
|
| DNA | 1 | 2006 | 1609 | 0.040 |
Why?
|
| Cell Death | 1 | 2021 | 239 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2022 | 369 | 0.040 |
Why?
|
| Syndrome | 2 | 2017 | 1121 | 0.040 |
Why?
|
| Platelet Count | 1 | 2020 | 138 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2006 | 2820 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2023 | 553 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2014 | 12412 | 0.040 |
Why?
|
| Intellectual Disability | 1 | 2006 | 1056 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2021 | 867 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2024 | 3350 | 0.030 |
Why?
|
| Exons | 1 | 2020 | 798 | 0.030 |
Why?
|
| Apolipoprotein L1 | 1 | 2016 | 11 | 0.030 |
Why?
|
| Duffy Blood-Group System | 1 | 2016 | 8 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2024 | 1899 | 0.030 |
Why?
|
| Apolipoproteins | 1 | 2016 | 70 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2019 | 762 | 0.030 |
Why?
|
| Lipoproteins, HDL | 1 | 2016 | 101 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2016 | 250 | 0.030 |
Why?
|
| Young Adult | 2 | 2023 | 9069 | 0.030 |
Why?
|
| Leukocytes | 1 | 2016 | 212 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2016 | 470 | 0.030 |
Why?
|
| Neutrophils | 1 | 2016 | 381 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2019 | 837 | 0.030 |
Why?
|
| Middle Aged | 3 | 2023 | 26990 | 0.030 |
Why?
|
| Oncogene Proteins v-myb | 1 | 2013 | 4 | 0.030 |
Why?
|
| Algorithms | 1 | 2020 | 1630 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2016 | 507 | 0.030 |
Why?
|
| alpha-Thalassemia | 1 | 2013 | 13 | 0.030 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 2013 | 50 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2016 | 548 | 0.030 |
Why?
|
| Glucuronosyltransferase | 1 | 2013 | 68 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2006 | 8240 | 0.030 |
Why?
|
| Bilirubin | 1 | 2013 | 124 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 880 | 0.020 |
Why?
|
| V(D)J Recombination | 1 | 2011 | 6 | 0.020 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2011 | 10 | 0.020 |
Why?
|
| CRADD Signaling Adaptor Protein | 1 | 2009 | 4 | 0.020 |
Why?
|
| Fas-Associated Death Domain Protein | 1 | 2009 | 6 | 0.020 |
Why?
|
| Apoptotic Protease-Activating Factor 1 | 1 | 2009 | 11 | 0.020 |
Why?
|
| Tubulin Modulators | 1 | 2009 | 11 | 0.020 |
Why?
|
| Heat Shock Transcription Factors | 1 | 2009 | 19 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 729 | 0.020 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2009 | 37 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2009 | 137 | 0.020 |
Why?
|
| Biosensing Techniques | 1 | 2009 | 54 | 0.020 |
Why?
|
| Luminescent Proteins | 1 | 2009 | 156 | 0.020 |
Why?
|
| Protein Multimerization | 1 | 2009 | 128 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2009 | 319 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2009 | 348 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2009 | 627 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2009 | 806 | 0.020 |
Why?
|
| DNA Repair | 1 | 2011 | 585 | 0.020 |
Why?
|
| RNA Interference | 1 | 2009 | 502 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2011 | 1638 | 0.020 |
Why?
|
| Kinetics | 1 | 2009 | 1333 | 0.020 |
Why?
|
| Transfection | 1 | 2009 | 1069 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2009 | 772 | 0.020 |
Why?
|
| Ireland | 1 | 2004 | 28 | 0.010 |
Why?
|
| Mitochondria | 1 | 2009 | 680 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2009 | 890 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2004 | 399 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2021 | 16389 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 3440 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 5185 | 0.010 |
Why?
|
| Prognosis | 1 | 2011 | 4648 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2007 | 2397 | 0.010 |
Why?
|
| Diet | 1 | 2007 | 1140 | 0.010 |
Why?
|